Direct answers / cited
CJC-1295 Questions, Answered from the Record
The questions readers actually ask, answered first-sentence-first and sourced to the published literature.
Definitions and Variants
What is CJC-1295?
CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone, built on hGRF(1-29) with four protease-resistant substitutions; the DAC variant adds covalent serum-albumin conjugation for a multi-day half-life, while the no-DAC form is short-acting [2]. It is an unapproved research chemical.
What does CJC-1295 do?
It binds the GHRH receptor on pituitary somatotrophs and stimulates pulsatile growth-hormone release, which raises hepatic IGF-1 [2]. In healthy adults, single 30-60 ug/kg doses produced dose-dependent multi-fold GH increases and 1.5- to 3-fold IGF-1 increases lasting days [1].
What is CJC-1295 DAC?
It is the albumin-conjugated, long-acting variant of CJC-1295. In rats the conjugate gave a four-fold GH AUC increase over unconjugated hGRF(1-29) and was detectable in plasma beyond 72 hours [2]; in humans the estimated half-life is 5.8-8.1 days [1].
What is CJC-1295 with DAC?
CJC-1295 with DAC ('Drug Affinity Complex') carries a maleimidopropionyl linker that covalently binds the free thiol on Cys34 of circulating serum albumin, forming a peptide-albumin conjugate that extends the plasma half-life toward that of albumin — the multi-day, long-acting form [2].
Is CJC-1295 a steroid?
No. CJC-1295 is a peptide — a synthetic GHRH analog that acts on the GHRH receptor to stimulate the body's own growth-hormone release [2]. It is not an anabolic-androgenic steroid and does not bind androgen receptors.
What is CJC-1295 ipamorelin?
It refers to combining CJC-1295, a GHRH analog, with ipamorelin, a selective GH secretagogue (GHRP). Ipamorelin releases GH with minimal ACTH/cortisol or prolactin spillover [12], which is why it is a common research partner for GHRH analogs.
Dosing and Handling
How much CJC-1295 should I take?
There is no established human dose. Human PK studies used single subcutaneous doses of 30, 60 or 90 ug/kg [1][3]; animal work used fixed microgram doses [4]. Community 'protocols' are not derived from controlled human trials. This is a research-only compound with no approved dosing.
How much CJC-1295 DAC should I take?
No validated human DAC dose exists. The published human PK work used 30-90 ug/kg single subcutaneous doses, and the DAC variant's multi-day half-life (5.8-8.1 days) means exposure persists for days after a single dose [1]. Dosing claims online are not trial-derived.
How much CJC-1295 / ipamorelin should I take?
There is no validated human dose for the combination. The pairing rationale is mechanistic — a GHRH analog plus a selective GHRP acting through distinct receptors produce supra-additive GH release — and circulating 'protocols' are not derived from controlled human trials [12].
How to reconstitute CJC-1295?
In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated [12]. Oral bioavailability is negligible because it is a peptide, so studies administer it subcutaneously. This describes laboratory handling, not a human-use instruction.
Where to inject CJC-1295?
The route studied is subcutaneous injection — the primary route across the human PK literature [1][3] — and early GRF(1-29) work also used intravenous administration [12]. This reflects how the compound was administered in research, not a human-use directive.
Efficacy and the Ipamorelin Combination
Does CJC-1295 and ipamorelin work?
GHRH analogs and GHRPs act through distinct receptors and synergize, producing GH release greater than either alone — the mechanistic basis for the pairing [12]. There are no controlled human efficacy trials of the specific CJC-1295/ipamorelin combination in healthy adults.
Safety
Is CJC-1295 safe?
CJC-1295 is not approved for human use and has no large or long-term safety trials; published human data are limited to early PK studies [12]. Sustained GH/IGF-1 elevation raises theoretical concerns — fluid retention, insulin-sensitivity effects, the IGF-1/cancer epidemiology — and FDA briefing materials cited immunogenicity [12].
Are CJC-1295 peptides safe?
Safety is not established. CJC-1295 is unapproved with no long-term human trials; reported and theoretical concerns include fluid retention, insulin-sensitivity effects, the IGF-1/cancer epidemiologic signal, and immunogenicity flagged by the FDA [12]. Product quality from research suppliers is also unverified [6].
What are the side effects of CJC-1295?
GH-axis stimulation can cause fluid retention and edema (GH increases renal sodium reabsorption) and can affect insulin sensitivity [12]; sustained IGF-1 elevation carries a theoretical cancer-risk concern from epidemiology [12]. The FDA also cited immunogenicity. Human safety data are limited to short PK studies.
What to expect when taking CJC-1295?
In the human PK literature, single doses raised GH and IGF-1 for days while preserving GH pulsatility [1][3]. This site describes measured research outcomes only — it does not promise results, and CJC-1295 is not approved for human use [4].
Does CJC-1295 affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis; it is not a testosterone-raising agent, and the published research does not characterize a direct testosterone effect [12]. Claims that it raises or lowers testosterone are not supported by the peer-reviewed CJC-1295 literature.
Does CJC-1295 lower testosterone?
There is no peer-reviewed evidence that CJC-1295 lowers testosterone. It works on the GHRH receptor and the GH/IGF-1 axis [2], a separate endocrine pathway from gonadal testosterone production.
Are peptides safer than TRT?
This is not a question the CJC-1295 literature answers. Testosterone-replacement therapy and GHRH-analog research are different interventions on different axes; CJC-1295 is unapproved with no comparative safety trials against TRT [12]. Any safety comparison would be speculative.
Regulatory and Detection
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved by the FDA (or any major regulator) for human use; it is handled as a research chemical [4]. At the 2024 FDA Pharmacy Compounding Advisory Committee it was reviewed and not recommended for the 503A compounding bulks list [12].
How is CJC-1295 detected in anti-doping testing?
CJC-1295 has been structurally identified by high-resolution LC-MS/MS [6] and is detectable by validated immuno-PCR and antibody-free LC-MS/MS assays; mid-size (2-10 kDa) peptide [13] and urinary nano-LC-MS methods [14] from 2024-2025 now cover the GHRH-analog class in routine doping control.
What is CJC-1295's WADA status for tested athletes?
CJC-1295 is prohibited at all times — in and out of competition — under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) of the WADA Prohibited List [4], and is banned by bodies such as the NCAA.